Group 1: Company Developments - Han Yi Co., Ltd. plans to reduce its shareholding by up to 2,940,000 shares, accounting for 3% of the total share capital, due to the shareholder's personal financial needs [1] - Novo Nordisk aims to launch the oral version of its weight loss drug, Semaglutide (Wegovy), in the U.S. early next year, highlighting its competitive advantages over rivals [2] - Chery Automobile's IPO in Hong Kong has reportedly received full subscription, seeking to raise up to HKD 9.14 billion [4] - Qingtian Technology has completed a Pre-A round financing of several hundred million yuan, led by Shenzhen Qianhai Ark [5] - MaiMai Technology has also completed a Pre-A round financing exceeding 100 million yuan, with a post-investment valuation exceeding 1 billion yuan [5] Group 2: Industry Insights - Meta's CEO Mark Zuckerberg believes AI glasses will be a primary means of integrating superintelligence into daily life, indicating a significant growth potential in the AI eyewear market [1] - The global smart eyewear market is projected to reach 2.555 million units shipped in Q2 2025, a 54.9% year-on-year increase, with China's market expected to see a 145.5% growth [8] - The Chinese government is confident in completing the core tasks of state-owned enterprise reform by the end of the year, which may impact the overall business environment [9]
氪星晚报｜通义DeepResearch模型、框架、方案全开源；奇瑞汽车香港IPO据悉已获足额认购；诺和诺德：拟于明年年初在美国“全面”推出口服版司美格鲁肽